Publications by authors named "N Klepac"
Background: Individuals with specific gene variants that encode for a Triggering Receptor Expressed on Myeloid cells 2 have a higher prevalence of Alzheimer's disease (AD). By interacting with amyloid and apolipoproteins, the TREM2 receptor regulates the number of myeloid cells, phagocytosis, and the inflammatory response. Higher expression has been suggested to protect against AD.
View Article and Find Full Text PDFArticle Synopsis
- A decrease in serotonergic transmission is an early sign of Alzheimer's disease (AD) and affects serotonin receptors, impacting behavioral and psychological symptoms in patients.
- The study analyzed 115 AD patients, 53 with mild cognitive impairment, and 2701 healthy controls to see if specific gene polymorphisms were linked to faster disease progression and AD-related pathology.
- Findings showed significant associations between certain genetic markers and changes in cerebrospinal fluid biomarkers, as well as poorer cognitive performance, suggesting these polymorphisms may play a role in AD's development and progression.
Background: It is estimated that up to 90% of patients with dementia are affected by behavioral and psychiatric symptoms during the course of the disease. The aim of this study was to investigate the prevalence of depression in dementia and mild cognitive impairment (MCI), the use of benzodiazepines and antidepressants among them and the impact of former education on their cognitive decline.
Subjects And Methods: In the study we have enrolled 100 patients with clinical diagnoses of either MCI or dementia, as was established by a single cognitive neurology subspecialist.
Article Synopsis
- * There has been a steady annual increase in DMT usage (9%) and associated costs (14.6%), with specific treatments like IFN-beta 1-a seeing particularly rapid growth.
- * New DMTs such as dimethyl fumarate and fingolimod are now available, but access is limited in Croatia compared to other countries, indicating a potential for continued growth in prescriptions and costs in the future.
Background: The dopaminergic system is functionally compromised in Alzheimer's Disease (AD). The activity of Monoamine Oxidase B (MAOB), the enzyme involved in the degradation of dopamine, is increased during AD. Also, increased expression of MAOB occurs in the postmortem hippocampus and neocortex of patients with AD.
View Article and Find Full Text PDF